Nature Reviews Drug Discovery

Article	Citations
The importance of persistence in cancer drug development	1810
A new path to targeted protein degradation?	1728
A specific biomarker for insoluble tau	1100
Targeting tumour-associated bacteria	1069
The improving benefit–risk balance of phase I cancer trials	935
Neutralizing Zika virus	735
Upcoming market catalysts in Q3 2021	716
Vaccine exposes tumours to immune cell attack	673
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	638
Promoting tissue repair after heart attack	533
mRNA-encoded monoclonal antibody fights CHIKV	523
AI serves up target and inhibitor for lung fibrosis	474
FDA approves first all-oral sleeping sickness drug	470
Hypoimmune iPSCs escape immune detection	460
Anti-tau antibody stumbles in phase II Alzheimer trial	398
Glucose-sensitive insulin protects against hypoglycaemia	390
Tumour cells get a dendritic cell makeover	384
Degrading cell-free DNA to prevent recurrent stroke	381
FDA new drug approvals in Q1 2023	369
Apolipoprotein L2 inhibitor mitigates fibrosis	360
Lipid nanoparticle ferries therapeutic mRNA to the placenta	356
New antibiotic for urinary tract infections nabs FDA approval	354
FDA approves second TTR stabilizer for cardiac amyloidosis	353
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	352
Targeting drug-resistant glioblastoma	349

First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	342
Evolution of innovative drug R&D in China	327
Top companies and drugs by sales in 2021	323
2022 FDA approvals	311
Chemical engineering of CRISPR–Cas systems for therapeutic application	265
Small-molecule discovery through DNA-encoded libraries	262
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	254
mRNA vaccines for infectious diseases — advances, challenges and opportunities	246
Increasing the potency of T cell therapies	240
Pushing both sides of the drug pricing aisle	238
Predicting Alzheimer disease dementia	235
Reflections on 10 years of the FDA’s breakthrough therapy designation	232
Blocking breast cancer metastasis	229
Rewired proteostasis in KRAS inhibitor resistance	216
Small molecule improves muscle function in myasthenia gravis	208
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	198
R&D re-balancing act	195
Host-directed antiviral blocks SARS-CoV-2 entry	186
Inhibiting ASGR1 boosts cholesterol removal	184
The significance of blockbusters in the pharmaceutical industry	178
Base editors hit the clinic	174
Combating antimicrobial resistance in malaria, HIV and tuberculosis	173
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	167
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	149
TCR-engineered T cells get personal	148
Screening ultra-large virtual libraries	147
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	146
A call to action for translational sciences in COVID-19 and future pandemics	144
FDA approves second BCMA-targeted CAR-T cell therapy	141
FDA new drug approvals in Q2 2023	141
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	139
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	138
The antibody–drug conjugate landscape	136
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	135
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	134
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	131
Phenotypic drug discovery: recent successes, lessons learned and new directions	125
The emerging role of mass spectrometry-based proteomics in drug discovery	122
Pan-coronavirus vaccine pipeline takes form	115
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	110
Antibody–drug conjugates come of age in oncology	106
Ribosome inhibitor combats bacterial drug resistance	105
A novel single-agent antibiotic	100
Gut metabolite mediates nerve repair	100
Agonist antibody lowers blood pressure	100
Reducing IL-2 toxicity	100
Immunology on the brain	98
Multi-TACs target solid tumours	94
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	94
What does AlphaFold mean for drug discovery?	92

The malignant melanoma market	91
Neglected tropical diseases go global	89
Monkeypox mRNA vaccine protects mice and macaques	88
The European Innovation Network as a hub for medicines innovation in Europe	87
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	85
Anti-IL-11 antibody shows anti-ageing properties	85
Author Correction: PI3K inhibitors are finally coming of age	84
LRRK2-targeted Parkinson disease drug advances into phase III	83
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	83
Avidity in antibody effector functions and biotherapeutic drug design	79
Frameworks for transformational breakthroughs in RNA-based medicines	78
Engineered parasite delivers proteins to the brain	77
Engineering a compact genome-editing tool	75
Docking downstream to treat myasthenia	72
Upcoming market catalysts in Q4 2023	70
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	70
Covalent inhibitor engages oncogenic AKT kinase	69
Delivering genome editing tools to primary cells	69
RNA structure guides antiviral ASO design	69
Accelerating precision oncology by converging pragmatic trials and real-world evidence	68
FDA approves first PSMA-targeted radiopharmaceutical	66
Giving antibiotics a boost	66
A rush of CRISPR to the lungs	65
Publisher Correction: Roflumilast	65
MYC in cancer: from undruggable target to clinical trials	63
Pushing the envelope with PCSK9	63
The PROTACtable genome	63
Promoting efferocytosis heals diabetic wounds	63
Investigating the origins of recent pharmaceutical innovation	62
Identification of neoantigens for individualized therapeutic cancer vaccines	61
AAV-based in vivo gene therapy for neurological disorders	61
V-ATPase inhibitor targets Ras-mutant cancers	59
Three-step cures for autoimmune diseases?	57
A bacteria-derived oral tumour vaccine	57
Immuno-oncology target TIGIT attracts a new contender	55
RNA delivery heats up cold tumours	54
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases	53
Designing novel macrocyclic drugs	52
Microbial ‘dark matter’ yields new antibiotic	51
Upcoming market catalysts in Q4 2024	50
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	49
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	48
Can large, simple trials bring drug developers back to common diseases?	47
Analysis of China-to-West pharmaceutical licensing deals in 2024	45
2023 FDA approvals: unprecedented volume at moderate value	41
Glue-based KRAS inhibitors make their debut cancer trial mark	40
Novel strategies to manage CAR-T cell toxicity	38
Cartilage regeneration for osteoarthritis	37
eEF2K: an atypical kinase target for cancer	36
The market for ulcerative colitis	35
The case for cell-penetrating peptides	35
PPAR agonists provide new treatment options for inflammatory liver disease	35
Therapeutically harnessing extracellular vesicles	34
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	33
Synthetic cytokine circuit targets solid tumours	33
miR-21 antagomir reverses COPD pathology	32
Refining HIV pre-exposure prophylactic agents	32
Targeting sigma receptor 1 in long QT syndrome	31
Designing closure-stabilizing integrin inhibitors	31
Transcription reprogramming to enhance CAR-T cell function	31
Publisher Correction: Evolution of the market for mRNA technology	30
A faster route to antidepressant activity	30
Designing a novel synthetic receptor	30
FDA approves PI3Kα inhibitor that does double duty as a degrader	30
A step closer to in vivo editing of haematopoietic stem cells	28
Anti-histamines boost immunotherapy	28
Novel schizophrenia therapy filed for FDA approval	28
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	28
FDA approves 21-valent pneumococcal vaccine	27
FDA approves decades-old maribavir for CMV infection	27
Improving efficacy of ASO therapy in SMA	26
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	25
In vivo CAR T cells move into clinical trials	25
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	25
Sequential immunotherapy: towards cures for autoimmunity	24
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	24
Top product forecasts for 2025	24
Targeting galectin-driven regulatory circuits in cancer and fibrosis	23
Kinase drug discovery 20 years after imatinib: progress and future directions	23
CAR T cells take to the airways	23

Drugging the efferocytosis process: concepts and opportunities	23
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	23
Genome-editing medicinal products: the EMA perspective	23
Bacteria tag tumours for CAR-T cell attack	22
Understanding the effects of antibiotic combinations	22
RNAi-based drug design: considerations and future directions	22
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	22
Synthesizing portimines	21
New target for anorexia	21
Putting a PIN in pancreatic cancer	20
Acyl-lysine reader inhibitor blocks AML progression	20
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	19
Rediscovering hygromycin A for Lyme disease treatment	19
Open-science drug discovery for COVID-19	18
Treating cannabis use disorder	18
Brain glucose mediates amphotericin B tolerance	17
Neurons give metastatic cells a push	17
Stalled molecular motor inhibits tumour growth	17
Epigenetic editor silences prion protein	17
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	17
Insights into new approach methodology innovation: an EMA perspective	16
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	15
The KRAS crowd targets its next cancer mutations	15
ASO targets DNA repair protein to combat Huntington disease	15
Trends in the drug target landscape for autoimmune diseases	15
Trustworthy AI for safe medicines	15
Thinking outside the box: non-canonical targets in multiple sclerosis	15
opnMe.com: a digital initiative for sharing tools with the biomedical research community	15
mRNA flu shots move into trials	14
Bispecific antibodies in oncology	14
RAS-targeted therapies	14
Advanced technologies for the development of infectious disease vaccines	14
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
Upcoming market catalysts in Q3 2023	13
A new antibiotic for A. baumannii	13
Antibody cocktail eliminates ebolaviruses	13
A type 1 regulatory T cell-based therapy	13
Understanding sphingosine-1-phosphate transport	13
Targeting ALDH1B1 in colorectal cancer	13
Alnylam scores big pharma support for angiotensinogen silencer	13
Nonhormonal target for endometriosis	12
Phosphatase inhibitor drives anticancer immune responses	12
Sensitizing glioblastoma to radiotherapy	12
FDA releases tissue-agnostic cancer drug draft guidance	12
Gene editing addresses antithrombin deficiency	12
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	12
Understanding immunomodulatory antibody agonism	12
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
Setting GPCRs free	11
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride	11
The renal cell carcinoma drug market	11
DUBTACs for targeted protein stabilization	11
Top product forecasts for 2022	11
Hooking FSH as a potential target for Alzheimer disease	11
Targeting cytokine networks in neuroinflammatory diseases	11
FDA approves PI3K inhibitor for a rare immune disorder	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
Macrophages as tools and targets in cancer therapy	10
Membrane transporters in drug development and as determinants of precision medicine	10
FDA approves first two drugs for rare Niemann–Pick disease	10
FDA approves first chikungunya vaccine	10
Targeting expanded trinucleotide repeats	10
Reactivating PTEN promotes antitumour immunity	10
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	10
RNF41 reverses liver fibrosis	9
Inhibiting metallo-β-lactamases	9
FDA approves second anti-amyloid antibody for Alzheimer disease	9
Novel drug targets in 2021	9
mRNA vaccine for Lyme disease prevention	9
Developing an IKZF2 glue degrader	9
Targeting ephrin signalling in sepsis	9
Two-pronged approach for macular degeneration	9
Chromatin-targeted drug discovery at “a very special moment”	9
Mapping cysteine ligandability	9
New route to target RAS	8
BacPROTAC to treat tuberculosis	8
The potential of innovative trial design for efficiently evaluating repurposed drugs	8
ALS antisense drug falters in phase III	8
Hitting SEND on mRNA delivery	8
2022 FDA approval number dips: a COVID-19 hangover?	8
Anti-tau antibody failures stack up	8
Opportunities for mitochondrial disease gene therapy	8
Scooping up all the drugs	8
Antibody drug conjugate combats inflammation	8
New therapeutic candidate for Chagas disease	8
Novel drug targets in 2023	8
Repurposing beta-blockers in breast cancer	8
Enhancing sensitivity to PARP inhibitors	7
Expanding HSCs without cytokines	7
Monoclonal antibody to treat fentanyl overdose	7
WRN inhibitors squeeze cancer cell vulnerability	7
Bivalent molecules unmute silenced genes	7
PROTAC induces HIV-1 Nef degradation	7
FDA approves first cell therapy for type 1 diabetes	7